LZTR1 and Miyoshi myopathy: Interestingly, data from the DepMap CRISPR dependency database indicates that LZTR1 preferentially functions as a tumor suppressor in KRAS-dependent MM versus in KRAS-driven adenocarcinomas (Fig. S4E)40.